Peet M, Bethell M S, Coates A, Khamnee A K, Hall P, Cooper S J, King D J, Yates R A
Br J Psychiatry. 1981 Aug;139:105-11. doi: 10.1192/bjp.139.2.105.
Fifty-three hospitalized chronic schizophrenic patients were treated with either propranolol, chlorpromazine or placebo in a double-blind randomized trials for up to three months. Propranolol in a usual dose of 640 mg/day, produced marked cardiovascular effects but no improvement in schizophrenic symptomatology relative to placebo. The effects of chlorpromazine were small and inconsistent.
在一项为期三个月的双盲随机试验中,53名住院慢性精神分裂症患者分别接受了普萘洛尔、氯丙嗪或安慰剂治疗。通常剂量为640毫克/天的普萘洛尔产生了明显的心血管效应,但与安慰剂相比,对精神分裂症症状并无改善。氯丙嗪的效果微小且不稳定。